For decades, Alzheimer’s research has largely revolved around one culprit: toxic protein buildups in the brain, especially amyloid-beta plaques. While that approach has delivered modest progress, it has also left major gaps, particularly for women and patients in late stages of the disease.
Now, a research team in China is testing a different idea. Instead of starting with plaques, they’re asking a more basic question: What if the Alzheimer’s brain is running out of energy?
An experimental treatment developed by scientists at the Kunming Institute of Zoology, under the Chinese Academy of Sciences, suggests that restoring the brain’s glucose supply could significantly improve memory and reduce brain damage—at least in mice.
What did the new Alzheimer’s study find?
In a study published on December 8 in the peer-reviewed journal Advanced Science, researchers reported that an experimental drug dramatically improved memory and reduced brain plaque in mice with late-stage Alzheimer’s-like disease.
Key findings from the trial
- Significant reversal of memory loss within weeks
- Near-normal cognitive performance in aged mice
- Reduced amyloid plaque accumulation in the brain
- Effects observed in late-stage Alzheimer’s models
Notably, the mice used in the study were 14–16 months old, roughly equivalent to advanced age in humans—an important detail given how few treatments work once Alzheimer’s has progressed.
Why glucose matters in Alzheimer’s disease
Alzheimer’s is the most common form of dementia, yet its root cause remains debated. While amyloid-beta plaques are a defining feature, they may not tell the whole story.
A different theory
The Kunming team’s hypothesis centers on glucose, the brain’s primary energy source.
Their argument:
- Brain cells require a steady glucose supply to function
- In Alzheimer’s disease, glucose delivery to brain tissue may fail
- This energy shortage could drive memory loss and cognitive decline
In other words, Alzheimer’s may be as much a metabolic disorder as a protein one.
This idea aligns with earlier research showing that glucose metabolism in the brain declines years before Alzheimer’s symptoms appear.
What is GLUT1, and why is it important?
At the heart of the study is a protein called GLUT1.
Think of GLUT1 as the brain’s fuel courier
- GLUT1 transports glucose from the bloodstream into brain cells
- Reduced GLUT1 means less fuel for neurons
- Previous studies have found lower GLUT1 levels in Alzheimer’s patients and animal models
“Previous studies have reported reduced GLUT1 expression in the brains of Alzheimer’s disease patients,” wrote Zhou Qixin, the study’s corresponding author.
Zhou, a professor at the institute’s Key Laboratory of Animal Models and Human Disease Mechanisms, linked this deficit to diabetes-related pathways—raising the possibility that Alzheimer’s and metabolic disorders may be more closely connected than previously thought.
How the experimental drug SL-ZF-01 works
To test their theory, the researchers developed a new compound called SL-ZF-01.
What is SL-ZF-01 made of?
The drug is derived from two bioactive compounds:
- Ferulic acid, linked to cerebrovascular health
- Butyric acid, known to boost ATP (cellular energy) production
These compounds were chosen because earlier studies suggested they could:
- Improve blood vessel function in the brain
- Enhance energy metabolism
- Support neuron survival
The goal was not just to reduce plaques, but to restore the brain’s energy system.
What happened when mice were treated?
The results were striking.
Memory and cognition
- Mice with Alzheimer’s-like disease showed rapid improvement in memory
- Performance returned to near-normal levels within weeks
- Improvements occurred despite the animals’ advanced age
Brain changes
- Significant reduction in amyloid plaque buildup
- Gene expression changes concentrated in the hippocampal dendritic zone
- A region critical for memory
- A known hotspot for Alzheimer’s damage
A ‘self-protection’ mechanism and how Alzheimer’s breaks it
The researchers uncovered another intriguing insight.
Healthy aging vs Alzheimer’s
- During normal aging, the brain appears to activate a self-protection mechanism
- This includes increasing GLUT1 expression to maintain energy supply
- Alzheimer’s disease may disrupt this process
SL-ZF-01 appeared to “restart” this protective mechanism, helping the brain regain its ability to fuel itself.
That framing reframes Alzheimer’s not just as damage accumulation but as a failure of repair and adaptation.
Why this matters for late-stage and female patients
Current Alzheimer’s treatments have major limitations.
Where existing drugs fall short
- Monoclonal antibody therapies targeting amyloid-beta:
- Primarily slow progression
- Work best in early-stage disease
- Show limited benefit in women
- No approved drugs effectively treat late-stage Alzheimer’s
The Kunming team’s findings are notable because:
- The treatment worked in late-stage disease
- It was tested exclusively in female mice
However, the researchers caution that results may not translate directly to males or humans.
What the study does not prove
The team was careful not to overstate its findings.
Important limitations
- The study does not prove that increased GLUT1 directly caused memory improvement
- Attempts to block GLUT1 using inhibitors failed due to high mortality in aged mice
- Causality remains unconfirmed
“Although our data strongly associate cognitive improvement with enhanced GLUT1 and bioenergetics, clear causal evidence is lacking,” Zhou wrote.
Future studies using gene editing may help determine whether GLUT1 is the key driver—or one part of a larger metabolic puzzle.
Why this research matters for China and the world
The stakes are especially high in China.
A growing dementia crisis
- Dementia cases in China have more than tripled in three decades
- Diagnosed cases rose from:
- ~4 million in 1990
- ~17 million in 2021
- A Fudan University study projects:
- Up to 115 million cases by 2050
That trajectory makes China a critical testing ground for new Alzheimer’s approaches—and a potential driver of global breakthroughs.
What comes next
SL-ZF-01 is still in the early experimental phase. Human trials, if they happen, are likely years away.
But the study adds momentum to a growing shift in Alzheimer’s research—one that treats the disease not only as a protein disorder, but as a crisis of brain energy.
If that idea holds up, future treatments may need to do more than clear plaques. They may need to refuel the brain itself.
TL;DR
- Chinese researchers tested a glucose-focused Alzheimer’s treatment in mice.
- The drug restored memory and reduced brain plaque in late-stage disease.
- It works by enhancing GLUT1, a protein that transports glucose into the brain.
- Results are promising but preliminary; causality is not yet proven.
- The approach could open new paths for treating late-stage and female patients.